We are very please to announce that our preliminary experience with a combination of metronomic chemotherapy and the introduction of target therapies with valproic acid , as an repositioned HDAC inhibitor as just been published by the indian journal of cancer. The study was lead by Dr Fousseiny Traore in the pediatric oncology unit of Bamako in Mali. Abstract Background: Metronomics is defined by the combination of metronomic chemotherapy and drug repositioning. Since off-patent (...)